Myovant Sciences Reports Results of Relugolix Combination Therapy in P-III LIBERTY 1 Study for Uterine Fibroids in Women
Shots:
- The P-III LIBERTY 1 study results involves assessing of relugolix (40mg) + estradiol (1.0mg) & norethindrone acetate (0.5mg)/relugolix (40mg) as monothx. + relugolix combination therapy vs PBO in 388 women in ratio (1:1:1) with uterine fibroids and heavy menstrual bleeding for 24wks.
- The P-III LIBERTY 1 study results: response rate (73.4% vs 18.9%); AEs (62% vs. 66%); 84.3% reduction in menstrual blood loss; maintained bone mineral density; reduction in pain; improvement in anemia; Improvement in QoL; well tolerated
- Relugolix is an oral GnRH receptor antagonist- reduces the ovarian estradiol production and is also evaluated in P-III LIBERTY 2 study with its expected results in Q3’19 and NDA submission to the US FDA in Q4’19
Ref: Myovant | Image: Twitter
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com